Horizon Pharma PLC (NASDAQ: HZNP) saw its shares hit a 52-week low on Monday after the company released its first-quarter financial results. The company said that it had $0.21 in EPS and $220.9 million…
Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.
AmpliPhi Biosciences saw its shares crater on Friday after the company announced that pricing of its secondary offering.
JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is companies that have strong new product cycles already in motion.
Shares of Pieris Pharmaceuticals saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca.
Many value investors have flocked to Gilead Sciences as the world's top biotech stock now that it is valued at a lower multiple than Big Pharma rivals.
Pfizer reported mixed first-quarter financial results before the markets opened on Tuesday.
Following the closing of the sale of three skincare brands to L'Oréal and after the closing of the divestiture of a manufacturing facility in Brazil, Valeant said that it now has further reduced its…
Intra-Cellular Therapies saw its stock crumble early on Monday after the company provided an update on its plan to submit a New Drug Application for its treatment of schizophrenia.
24/7 Wall St. has put together a preview of some of the world’s largest biotech and pharma companies reporting their earnings on Thursday.
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Express Scripts is among the biggest large cap losers on Wall Street on Tuesday. It's as if the market bounce doesn't even matter.
XBiotech saw its shares fall sharply after the company issued an update on its recent meeting with the European Medical Agency (EMA).
Shares of Immune Pharmaceuticals saw an incredible gain in Thursday’s session following the announcement of an exclusive license agreement.
